

# JosÃ© A. CarriÃ³n

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1048885/publications.pdf>

Version: 2024-02-01

125  
papers

3,778  
citations

218381

26  
h-index

133063

59  
g-index

134  
all docs

134  
docs citations

134  
times ranked

4130  
citing authors

#	ARTICLE	IF	CITATIONS
1	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196.	6.3	818
2	Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. <i>Liver Transplantation</i> , 2006, 12, 1791-1798.	1.3	379
3	Efficacy of Antiviral Therapy on Hepatitis C Recurrence After Liver Transplantation: A Randomized Controlled Study. <i>Gastroenterology</i> , 2007, 132, 1746-1756.	0.6	332
4	Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. <i>Hepatology</i> , 2006, 43, 492-499.	3.6	282
5	Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. <i>Journal of Hepatology</i> , 2009, 50, 719-728.	1.8	184
6	Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. <i>Hepatology</i> , 2010, 51, 23-34.	3.6	120
7	Donor and Recipient IL28B Polymorphisms in HCV-Infected Patients Undergoing Antiviral Therapy before and after Liver Transplantation. <i>American Journal of Transplantation</i> , 2011, 11, 1051-1057.	2.6	79
8	Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa registry. <i>Hepatology</i> , 2017, 65, 1810-1822.	3.6	78
9	Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. <i>Gastroenterology</i> , 2018, 155, 1120-1127.e4.	0.6	76
10	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). <i>Guía de práctica clínica. Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.2	71
11	Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation. <i>Gastroenterology</i> , 2010, 138, 147-158.e1.	0.6	68
12	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. <i>Journal of Hepatology</i> , 2019, 70, 874-884.	1.8	67
13	Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs. <i>Journal of Hepatology</i> , 2019, 71, 666-672.	1.8	67
14	Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. <i>Journal of Hepatology</i> , 2020, 72, 1112-1121.	1.8	62
15	Retransplantation in patients with hepatitis C recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2010, 53, 962-970.	1.8	61
16	Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C. <i>American Journal of Transplantation</i> , 2014, 14, 375-383.	2.6	53
17	Hepatitis C Virus Compartmentalization and Infection Recurrence after Liver Transplantation. <i>American Journal of Transplantation</i> , 2009, 9, 1591-1601.	2.6	51
18	Hepatitis B reactivation in patients with chronic hepatitis C undergoing antiviral therapy with an interferon-free regimen. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1156-1161.	1.9	47

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort. <i>Journal of Viral Hepatitis</i> , 2017, 24, 304-311.	1.0	40
20	Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. <i>Antiviral Research</i> , 2020, 174, 104694.	1.9	39
21	Severe acute hepatitis in the dress syndrome: Report of two cases. <i>Annals of Hepatology</i> , 2010, 9, 198-201.	0.6	34
22	Cyclosporine A-Based Immunosuppression Reduces Relapse Rate After Antiviral Therapy in Transplanted Patients With Hepatitis C Virus Infection: A Large Multicenter Cohort Study. <i>Transplantation</i> , 2011, 92, 334-340.	0.5	34
23	Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains. <i>Journal of General Virology</i> , 2010, 91, 1183-1188.	1.3	34
24	Microwave versus radiofrequency ablation for the treatment of liver malignancies: a randomized controlled phase 2 trial. <i>Scientific Reports</i> , 2022, 12, 316.	1.6	34
25	A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 926-933.	1.8	33
26	Impact of anthropometric features on the applicability and accuracy of FibroScan <sup>®</sup> (M and T) ETQq000 rgBT /Overlock 1746-1753.	1.4	31
27	Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1570-1578.	1.4	29
28	Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease. <i>American Journal of Gastroenterology</i> , 2017, 112, 1400-1409.	0.2	26
29	Applicability and accuracy improvement of transient elastography using the M and XL probes by experienced operators. <i>Journal of Viral Hepatitis</i> , 2015, 22, 297-306.	1.0	24
30	Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. <i>Journal of Viral Hepatitis</i> , 2018, 25, 811-817.	1.0	24
31	Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 226-237.	1.0	22
32	Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA- real-world cohort. <i>Journal of Viral Hepatitis</i> , 2019, 26, 55-64.	1.0	20
33	Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation. <i>Journal of Gastroenterology</i> , 2013, 48, 762-769.	2.3	19
34	Predictive model of mortality in patients with spontaneous bacterial peritonitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 44, 629-637.	1.9	19
35	Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients. <i>Journal of Gastroenterology</i> , 2020, 55, 205-216.	2.3	19
36	Recomendaciones para la detección, diagnóstico y seguimiento de los pacientes con enfermedad por hígado graso no alcohólico en atención primaria y hospitalaria. <i>Medicina Clínica</i> , 2019, 153, 169-177.	0.3	18

#	ARTICLE	IF	CITATIONS
37	Effectiveness and safety of obeticholic acid in a Southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 519-530.	1.9	17
38	Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection. <i>Revista EspaÃ±ola De Sanidad Penitenciaria</i> , 2017, 19, 87-97.	0.5	16
39	Sensitivity to antiviral therapy may change after liver transplantation in patients with chronic hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2006, 13, 544-551.	1.0	15
40	GuÃ­a de tratamiento de la infecciÃ³n por virus de la hepatitis C. AsociaciÃ³n EspaÃ±ola para el Estudio del HÃ¡gado (AEEH). <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2018, 41, 597-608.	0.2	15
41	Predicting the development of liver cirrhosis by simple modelling in patients with chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 364-374.	1.9	14
42	Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2850-2856.	1.3	13
43	Evolution of the NS3 and NS5B Regions of the Hepatitis C Virus During Disease Recurrence After Liver Transplantation. <i>American Journal of Transplantation</i> , 2007, 7, 2172-2179.	2.6	12
44	MR Elastography to Assess Liver Fibrosis. <i>Radiology</i> , 2008, 247, 591-592.	3.6	12
45	The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. <i>Journal of Hepatology</i> , 2015, 62, 311-316.	1.8	12
46	Enfermedad hepÃ¡tica por alcohol. GuÃ­as de prÃ¡ctica clÃ­nica. Documento de consenso auspiciado por la AEEH. <i>GastroenterologÃ­a Y HepatologÃ­a</i> , 2019, 42, 657-676.	0.2	12
47	Quantification of HBsAg to predict low levels and seroclearance in HBeAg-negative patients receiving nucleos(t)ide analogues. <i>PLoS ONE</i> , 2017, 12, e0188303.	1.1	12
48	High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4. <i>Liver International</i> , 2017, 37, 1823-1832.	1.9	10
49	Elastography is unable to exclude cirrhosis after sustained virological response in HCV-infected patients with advanced chronic liver disease. <i>Liver International</i> , 2021, 41, 2733-2746.	1.9	10
50	Diagnostic Accuracy of the Enhanced Liver Fibrosis (ELF®) Score Using HCV-Infected Serum Samples Cryopreserved for up to 25 Years. <i>PLoS ONE</i> , 2016, 11, e0164883.	1.1	10
51	Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 500-512.	1.9	9
52	Hemodynamic response to propranolol in patients with recurrent hepatitis C virus-related cirrhosis after liver transplantation: A case-control study. <i>Liver Transplantation</i> , 2013, 19, 450-456.	1.3	8
53	Treatment of Hepatitis C Virus in Patients with Advanced Cirrhosis: Always Justified? Analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2016, 64, S133.	1.8	8
54	Effectiveness and Safety of Sofosbuvir/Ledipasvir Treatment for Monoinfected Genotype 1 HCV Patients in Real-Life Clinical Practice: Results from Spanish Hepa-C Cohort. <i>Journal of Hepatology</i> , 2016, 64, S217-S218.	1.8	8

#	ARTICLE	IF	CITATIONS
55	Hepatitis B surface antigen and hepatitis B core-related antigen kinetics after adding pegylated-interferon to nucleos(t)ids analogues in hepatitis B e antigen-negative patients. <i>World Journal of Hepatology</i> , 2020, 12, 1076-1088.	0.8	8
56	Large spontaneous splenorenal shunt as a cause of chronic hepatic encephalopathy. <i>Journal of Hepatology</i> , 2004, 40, 868.	1.8	7
57	150 Antiviral therapy of patients with decompensated cirrhosis to prevent hepatitis C recurrence after liver transplantation. <i>Journal of Hepatology</i> , 2006, 44, S64.	1.8	7
58	Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2015, 21, 5421.	1.4	7
59	Effectiveness and Safety of Ombitasvir, Paritaprevir, Ritonavir and Dasabuvir Patients with Genotype 1 Chronic Hepatitis C Virus Infection: Results from the Spanish Real World Cohort. <i>Journal of Hepatology</i> , 2016, 64, S218-S219.	1.8	7
60	Foamy Histiocyte-Like Hepatocellular Carcinoma (HCC): A New Variant of HCC?. <i>Annals of Hepatology</i> , 2017, 16, 304-307.	0.6	7
61	Recommendations for the detection, diagnosis and follow-up of patients with non-alcoholic fatty liver disease in primary and hospital care. <i>Medicina Clínica (English Edition)</i> , 2019, 153, 169-177.	0.1	7
62	Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1319-1324.	1.0	7
63	On-therapy HBsAg kinetics can predict HBsAg loss after nucleos(t)ide analogues interruption in HBeAg-negative patients. The cup is half full and half empty. <i>Digestive and Liver Disease</i> , 2022, 54, 1044-1051.	0.4	7
64	Evaluation of a portable hemoglobinometer (HemoCue) to control anemia in hepatitis C liver transplant recipients undergoing antiviral therapy. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 942-947.	0.8	5
65	Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence. <i>Liver International</i> , 2015, 35, 1557-1565.	1.9	5
66	Simple prediction of long-term clinical outcomes in patients with mild hepatitis C recurrence after liver transplantation. <i>Transplant International</i> , 2016, 29, 698-706.	0.8	5
67	Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1100-1107.	1.4	5
68	FRI-225-Universal access to direct-acting antivirals treatment is not not enough to prevent late stage presentation of hepatitis C infection. <i>Journal of Hepatology</i> , 2019, 70, e493-e494.	1.8	5
69	Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-to-moderate fibrosis: Results from a real-world cohort. <i>Liver International</i> , 2019, 39, 90-97.	1.9	5
70	Neutrophil and Monocyte Function in Patients with Chronic Hepatitis C Undergoing Antiviral Therapy with Regimens Containing Protease Inhibitors with and without Interferon. <i>PLoS ONE</i> , 2016, 11, e0166631.	1.1	5
71	[87] EFFICACY OF ANTIVIRAL THERAPY ON DISEASE PROGRESSION IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A RANDOMIZED CONTROLLED STUDY. <i>Journal of Hepatology</i> , 2007, 46, S39-S40.	1.8	4
72	P0190 : Predictive model of mortality in cirrhotic patients with high risk spontaneous bacterial peritonitis. <i>Journal of Hepatology</i> , 2015, 62, S375.	1.8	4

#	ARTICLE	IF	CITATIONS
73	Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfecting with human immunodeficiency virus-1 in Spain. PLoS ONE, 2019, 14, e0225061.	1.1	4
74	Safety and efficacy of Sofosbuvir/Velpatasvir with and without Ribavirin in genotype 3HCV-infected patients with cirrhosis. Journal of Hepatology, 2018, 68, S20-S21.	1.8	3
75	PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis. Journal of Hepatology, 2019, 70, e113-e114.	1.8	3
76	Utilidad de la colonografía por tomografía computarizada en la detección de pólipos colorrectales. Medicina Clínica, 2004, 123, 41-44.	0.3	3
77	Impact of HCV cure with drug-acting antivirals in the use of concomitant medication and lipid profile: follow-up data 2 years after the sustained virological response. European Journal of Gastroenterology and Hepatology, 2021, 32, 214-222.	0.8	3
78	83 Transient elastography to evaluate the severity of hepatitis C recurrence after liver transplantation. Journal of Hepatology, 2006, 44, S37.	1.8	2
79	155 EFFICACY AND SAFETY OF STANDARD ANTIVIRAL THERAPY IN CIRRHOTIC PATIENTS AWAITING LIVER TRANSPLANTATION (LT). Journal of Hepatology, 2013, 58, S69-S70.	1.8	2
80	Platelet Count and Liver Stiffness Measurement to Exclude High-Risk Gastroesophageal Varices in Patients with HCV-Cirrhosis. A Multicentric Study. Journal of Hepatology, 2016, 64, S273.	1.8	2
81	Safety and Efficacy of Sofosbuvir plus Simeprevir in a Spanish Cohort of 622 Cirrhotic Patients Infected with Genotypes 1 or 4. Journal of Hepatology, 2016, 64, S831.	1.8	2
82	Letter: hepatitis B reactivation in patients with chronic hepatitis C during direct-acting antiviral therapy authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 45, 1559-1560.	1.9	2
83	Living donor liver transplantation and hepatitis C: Lessons from the learning curve?. Liver Transplantation, 2007, 13, 18-20.	1.3	1
84	Noninvasive tests in the post-liver transplantation setting. Liver Transplantation, 2007, 13, 628-629.	1.3	1
85	108 EARLY ASSESSMENT OF LIVER STIFFNESS IDENTIFIES TWO DIFFERENT PATTERNS OF LIVER FIBROSIS PROGRESSION IN PATIENTS WITH HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION. Journal of Hepatology, 2008, 48, S48.	1.8	1
86	Antiviral therapy in HCV-infected cirrhotic patients awaiting liver transplantation. Journal of Hepatology, 2009, 51, 960-962.	1.8	1
87	P1135 ADDITION OF TELAPREVIR OR BOCEPREVIR TO PEG-RIB THERAPY INCREASES THE RISK OF INFECTIONS IN PATIENTS WITH HEPATITIS C-RELATED CIRRHOSIS (HCV-CH): A COMPARATIVE STUDY. Journal of Hepatology, 2014, 60, S460.	1.8	1
88	Clinical Value of Thyrotropin Receptor Antibodies for the Differential Diagnosis of Interferon Induced Thyroiditis. Experimental and Clinical Endocrinology and Diabetes, 2016, 124, 39-44.	0.6	1
89	Efficacy and Safety of HCV-Treatment with Direct-Acting Antiviral Agents Interferon-Free, in Patients with Severe Renal Impairment in Clinical Practice. Journal of Hepatology, 2016, 64, S779.	1.8	1
90	Impact of sustained virological response with DAAs in patients with compensated HCV cirrhosis and endoscopic esophageal varices study. Journal of Hepatology, 2017, 66, S717.	1.8	1

#	ARTICLE	IF	CITATIONS
91	Aplastic Anemia and Severe Myelosuppression with Boceprevir or Simeprevir-Containing Hepatitis C Virus Treatment. <i>Annals of Hepatology</i> , 2017, 16, 312-317.	0.6	1
92	THU-300-Prevalence of NAFLD in patients with a first episode of stroke and impact on the mortality and severity at 3 months. <i>Journal of Hepatology</i> , 2019, 70, e292.	1.8	1
93	Multi-organ Involvement in Non-pulmonary Sarcoidosis. <i>ReumatologÃ­a ClÃ­nica</i> , 2021, , .	0.2	1
94	14 EFFICAY AND SAFETY OF PEGYLATED INTERFERON AND RIBAVIRIN IN HCV-INFECTED PATIENTS AWAITING LIVER TRANSPLANTATION: A CASE-CONTROL STUDY. <i>Journal of Hepatology</i> , 2008, 48, S8.	1.8	0
95	PIN62 A Multidisciplinary Support program in Hepatitis C Treatment: An Economic Evaluation. <i>Value in Health</i> , 2011, 14, A276.	0.1	0
96	30 A COMBINATION OF BASELINE VARIABLES INCLUDING IL28B POLYMORPHISM CAN ACCURATELY PREDICT RESPONSE TO ANTIVIRAL TREATMENT IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2011, 54, S14.	1.8	0
97	531 EARLY IDENTIFICATION OF TWO PATTERNS OF HEPATITIS C RECURRENCE (RAPID AND SLOW) Tj ETQq1 1 0.784314 rgBT /Overlock of <i>Hepatology</i> , 2011, 54, S217-S218.	1.8	0
98	207 PERIportal SINUSOIDAL FIBROSIS IS AN EARLY MARKER OF PORTAL HYPERTENSION AND SIGNIFICANT FIBROSIS IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION. <i>Journal of Hepatology</i> , 2012, 56, S88.	1.8	0
99	156 HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: MAINTENANCE THERAPY WITH PEGYLATED INTERFERON IN NONRESPONDERS TO STANDARD THERAPY SLOWS THE DISEASE PROGRESSION AND IMPROVES SURVIVAL. <i>Journal of Hepatology</i> , 2013, 58, S70.	1.8	0
100	801 LONG-TERM EVOLUTION OF LIVER FIBROSIS IN MILDâ€“MODERATE CHRONIC HEPATITIS C: STUDY WITH PAIRED BIOPSIES. <i>Journal of Hepatology</i> , 2013, 58, S327-S328.	1.8	0
101	729 VARIABLES RELATED TO INADEQUATE LIVER STIFFNESS MEASUREMENTS USING TRANSIENT ELASTOGRAPHY. ANALYSIS OF 895 EXAMINATIONS. <i>Journal of Hepatology</i> , 2013, 58, S295-S296.	1.8	0
102	713 IMPROVEMENT OF TRANSIENT ELASTOGRAPHY APPLICABILITY TO EVALUATE LIVER STIFFNESS BY TRAINED OPERATORS AND USING XL PROBE. <i>Journal of Hepatology</i> , 2013, 58, S289-S290.	1.8	0
103	P1201 UTILITY OF SERUM MARKERS AND TRANSIENT ELASTOGRAPHY TO IDENTIFY SERIOUS ADVERSE EFFECTS DURING ANTIVIRAL THERAPY IN HCV INFECTED CIRRHOTIC PATIENTS. A MULTICENTER STUDY. <i>Journal of Hepatology</i> , 2014, 60, S488.	1.8	0
104	O39 LONG TERM OUTCOME OF MILD HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A LARGE PROSPECTIVE STUDY. <i>Journal of Hepatology</i> , 2014, 60, S17.	1.8	0
105	P0846 : Evaluation of adherence to telaprevir (TVR) and boceprevir (BOC) using different thresholds. <i>Journal of Hepatology</i> , 2015, 62, S656.	1.8	0
106	P0515 : Biological stability and diagnostic accuracy of ELFÃ© (enhanced liver fibrosis test) to identify liver fibrosis in patients with chronic hepatitis C using cryopreserved serum samples during 25 years. <i>Journal of Hepatology</i> , 2015, 62, S508.	1.8	0
107	Quantification of HBsAg (HBsAg-Q) in HBeAg-Negative Patients Receiving Nucleos(T)ide Analogues to Predict the Loss of HBsAg. <i>Journal of Hepatology</i> , 2016, 64, S379.	1.8	0
108	Non-Invasive Assessment of Steatosis and Liver Fibrosis in Overweight and Obese Patients. <i>Journal of Hepatology</i> , 2016, 64, S500.	1.8	0

#	ARTICLE	IF	CITATIONS
109	Enhanced Liver Fibrosis (ELF) Test Quantification in HBeAg-Negative Patients with Nucleos(T)ide Analogues 1, 3, 5 and 8 Years after Liver Biopsy. <i>Journal of Hepatology</i> , 2016, 64, S730.	1.8	0
110	Prevalence and Management of Drug-Drug Interactions (DDIs) with Ombitasvir (OBV), Paritaprevir/R (PRV/r) ± Dasabuvir (DBV) ± Ribavirin (RBV) in Patients with Chronic Hepatitis C in Real-Life Clinical Practice. <i>Journal of Hepatology</i> , 2016, 64, S761.	1.8	0
111	Non-Invasive Evaluation of Chronic Hepatitis C Patients with Moderate Fibrosis (F2) Long-Term Impact of Antiviral Treatment. <i>Journal of Hepatology</i> , 2016, 64, S726.	1.8	0
112	Molecular characterization of Hepatitis C virus resistance-associated substitutions after interferon-free treatment failure by massive parallel sequencing. <i>Journal of Hepatology</i> , 2017, 66, S731.	1.8	0
113	High efficacy and tolerability of hepatitis C genotype 2 treatment with direct-acting antivirals in real world: analysis of the Hepa-C Registry. <i>Journal of Hepatology</i> , 2017, 66, S311.	1.8	0
114	Survival analysis and response to ursodeoxycholic acid in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2017, 66, S352.	1.8	0
115	Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response. <i>Journal of Hepatology</i> , 2017, 66, S494.	1.8	0
116	Increased risk of liver cancer in cirrhotic patients associated to direct acting antivirals. <i>Journal of Hepatology</i> , 2018, 68, S118.	1.8	0
117	Body mass index influences Controlled Attenuation Parameter (CAP) values measured with Fibroscan Å® M probe. When should we evaluate steatosis with the XL probe?. <i>Journal of Hepatology</i> , 2018, 68, S576-S577.	1.8	0
118	Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years. <i>Journal of Hepatology</i> , 2018, 68, S218-S219.	1.8	0
119	Controlled attenuation parameter values of Fibroscan Å® compatible with steatosis in patients with chronic hepatitis C and changes after sustained virological response. <i>Journal of Hepatology</i> , 2018, 68, S543-S544.	1.8	0
120	Impact of sustained virological response in the use of concomitant drugs in hepatitis C virus infected patients with comorbidities. <i>Journal of Hepatology</i> , 2018, 68, S547.	1.8	0
121	THU-124-Efficacy and safety of glecaprevir/pibrentasvir for the pangenotypic treatment of chronic hepatitis C in former intravenous drug users: Subanalysis from a Spanish real-world cohort (Hepa-C). <i>Journal of Hepatology</i> , 2019, 70, e213-e214.	1.8	0
122	IDDF2019-ABS-0212â€¦Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis. , 2019, , .		0
123	1058â€œfReal World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis. <i>American Journal of Gastroenterology</i> , 2019, 114, S599-S600.	0.2	0
124	Multi-organ Involvement in Non-pulmonary Sarcoidosis. <i>ReumatologÃ­a ClÃ­nica (English Edition)</i> , 2022, 18, 309-311.	0.2	0
125	Author's reply: Nucleo(s)tide analogue withdrawal in chronic hepatitis B virus infection. Beyond the HBsAg loss. <i>Digestive and Liver Disease</i> , 2022, , .	0.4	0